INTS vs. IPHA, ADAP, ARTV, BDTX, CRBU, CHRS, TCRX, CDTX, SLDB, and EDIT
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Innate Pharma (IPHA), Adaptimmune Therapeutics (ADAP), Artiva Biotherapeutics (ARTV), Black Diamond Therapeutics (BDTX), Caribou Biosciences (CRBU), Coherus BioSciences (CHRS), TScan Therapeutics (TCRX), Cidara Therapeutics (CDTX), Solid Biosciences (SLDB), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Intensity Therapeutics, Inc. Common stock vs.
Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
Intensity Therapeutics, Inc. Common stock currently has a consensus price target of $8.50, suggesting a potential upside of 274.45%. Innate Pharma has a consensus price target of $11.50, suggesting a potential upside of 542.46%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Intensity Therapeutics, Inc. Common stock.
In the previous week, Innate Pharma had 1 more articles in the media than Intensity Therapeutics, Inc. Common stock. MarketBeat recorded 4 mentions for Innate Pharma and 3 mentions for Intensity Therapeutics, Inc. Common stock. Intensity Therapeutics, Inc. Common stock's average media sentiment score of 1.89 beat Innate Pharma's score of 1.19 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the media.
Innate Pharma has higher revenue and earnings than Intensity Therapeutics, Inc. Common stock.
Intensity Therapeutics, Inc. Common stock has a beta of 3.98, indicating that its stock price is 298% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
Innate Pharma's return on equity of 0.00% beat Intensity Therapeutics, Inc. Common stock's return on equity.
3.7% of Intensity Therapeutics, Inc. Common stock shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 18.6% of Intensity Therapeutics, Inc. Common stock shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Innate Pharma received 35 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 100.00% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 58.44% of users gave Innate Pharma an outperform vote.
Summary
Innate Pharma beats Intensity Therapeutics, Inc. Common stock on 9 of the 14 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
This page (NASDAQ:INTS) was last updated on 1/30/2025 by MarketBeat.com Staff
